Improved PFS With Addition of Idelalisib to Ofatumumab in Previously Treated CLL

May 29-June 2, 2015; Chicago, Illinois
Results of an open-label phase III trial investigating the safety and efficacy of adding idelalisib to ofatumumab in pretreated CLL.
Format: Microsoft PowerPoint (.ppt)
File Size: 694 KB
Released: June 5, 2015

Acknowledgements

Educational grant provided by:
AstraZeneca
Bayer HealthCare Pharmaceuticals Inc.
Bristol-Myers Squibb
Celgene Corporation
Genentech BioOncology
Incyte
Novartis Pharmaceuticals Corporation

Related Content

In this slideset from Clinical Care Options (CCO), experts provide insights on the optimal use of CAR T-cell therapy for ALL

Jae H. Park, MD Released: June 16, 2021

In this slideset from Clinical Care Options (CCO), experts provide insights on CAR T-cell strategies for myeloma

Noopur Raje, MD Released: June 16, 2021

In this slideset from Clinical Care Options (CCO), experts provide insights on the optimal use of CAR T-cell therapy for lymphomas

person default Caron A. Jacobson, MD Released: June 16, 2021

Downloadable summary slideset of key takeaways from a live NCCN/CCO Webinar focused on current treatment in CLL/SLL.

Jeremy S. Abramson, MD, MMSc Anthony Mato, MD William G. Wierda, MD, PhD Released: June 15, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue